Golvatinib

Golvatinib, also known as E-7050, is an investigational, orally bioavailable small-molecule drug that functions as a potent dual inhibitor of the c-Met (HGF receptor) and VEGFR-2 tyrosine kinases. By blocking these receptors, it aims to suppress tumor growth, survival, migration, and angiogenesis in various cancers.Developed initially by Eisai, this compound was mainly investigated for the treatment of advanced solid tumors, including gastric cancer, hepatocellular carcinoma, and platinum-resistant squamous cell carcinoma of the head and neck. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include golvatinibum. Its PubChem CID is 16118392.

CAS No 928037-13-2
Molecular Formula C33H37F2N7O4
Molecular Weight 633.70 g/mol
Synonyms 1-N'-[2-fluoro-4-[[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]-4-pyridinyl]oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Frequently Asked Questions